Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results
Transformation Not Yet Complete, Says Departing R&D Chief
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
You may also be interested in...
The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.